The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
Open accessAbstract
A new coronavirus, referred to as SARS-CoV-2, is responsible for the recent outbreak of severe respiratory disease. This outbreak first detected in Wuhan, China in December 2019, has spread to other regions of China and to 25 other countries as of January, 2020. It has been known since the 2003 SARS epidemic that the receptor critical for SARS-CoV entry into host cells is the angiotensin-converting enzyme 2 (ACE2). The S1 domain of the spike protein of SARS-CoV attaches the virus to its cellular receptor ACE2 on the host cells. We thought that it is timely to explain the connection between the SARS-CoV, SARS-CoV-2, ACE2 and the rationale for soluble ACE2 as a potential therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
Menachery, V. D., Yount, B. L., Debbink, K., Agnihothram, S., Gralinski, L. E., Plante, J. A., Graham, R. L., Scobey, T., Ge, X.-Y., Donaldson, E. F., et al. (2015) · Nature Medicine · doi:10.1038/nm.3985 · Cited by 901
Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2
Zhao, Y., Zhao, Z., Wang, Y., Zhou, Y., Ma, Y., & Zuo, W. (2020) · doi:10.1101/2020.01.26.919985 · Cited by 860
Wysocki, J., Ye, M., Rodriguez, E., González-Pacheco, F. R., Barrios, C., Evora, K., Schuster, M., Loibner, H., Brosnihan, K. B., Ferrario, C. M., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.138420 · Cited by 300
Self-citationAngiotensin-Converting Enzyme 2 (ACE2) in Disease Pathogenesis
Imai, Y., Kuba, K., Ohto-Nakanishi, T., & Penninger, J. M. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0045 · Cited by 198
Cited by
The pivotal link between ACE2 deficiency and SARS-CoV-2 infection
Verdecchia, P., Cavallini, C., Spanevello, A., & Angeli, F. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.037 · Cited by 1,237
“[69,70] In this context, administration of soluble recombinant ACE2 [12] or angiotensin1-7 [71] could be promising therapeutic approaches, requiring urgent evaluation in clinical trials.”
Beyerstedt, S., Casaro, E. B., & Rangel, É. B. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-04138-6 · Cited by 897
The presence of SARS‐CoV‐2 RNA in the feces of COVID‐19 patients
Chen, Y., Chen, L., Deng, Q., Zhang, G., Wu, K., Ni, L., Yang, Y., Liu, B., Wang, W., Wei, C., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25825 · Cited by 833
COVID-19: Immunology and treatment options
Felsenstein, S., Herbert, J. A., McNamara, P. S., & Hedrich, C. M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108448 · Cited by 669
ACE2: The Major Cell Entry Receptor for SARS-CoV-2
Scialo, F., Daniele, A., Amato, F., Pastore, L., Matera, M. G., Cazzola, M., Castaldo, G., & Bianco, A. (2020) · Lung · doi:10.1007/s00408-020-00408-4 · Cited by 481
Metadata
- Authors
- Batlle, D., Wysocki, J., & Satchell, K.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2020-03
- Volume
- 134
- Issue
- 5
- Pages
- 543-545
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W3011995143
- Cited by
- 444
- References
- 12
- FWCI
- 12.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? https://app.cochat.ai/papers/10.1042/cs20200163
- The paper
- Batlle, D., Wysocki, J., & Satchell, K. (2020). Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clinical Science. https://doi.org/10.1042/cs20200163
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.